Acute Repetitive Seizures Market Size
Study Period | 2019 - 2029 |
Market Size (2024) | USD 2.62 Billion |
Market Size (2029) | USD 4.84 Billion |
CAGR (2024 - 2029) | 13.05 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Acute Repetitive Seizures Market Analysis
The Acute Repetitive Seizures Market size is estimated at USD 2.62 billion in 2024, and is expected to reach USD 4.84 billion by 2029, at a CAGR of 13.05% during the forecast period (2024-2029).
Factors such as the rising burden of seizures, coupled with a growing aging population and increasing research and development activities, are expected to boost the growth of the acute repetitive seizures market over the forecast period.
As the prevalence of epilepsy and other seizure disorders rises, the demand for effective treatments intensifies. This surge can be attributed to factors such as genetic predisposition, head injuries, and various neurological conditions. For instance, data released by the World Health Organization in February 2024 indicated that approximately 5 million individuals were diagnosed with epilepsy annually on a global scale. Furthermore, data from the World Health Organization in February 2023 highlighted that around 50 million people worldwide were living with epilepsy, solidifying its status as one of the most prevalent neurological disorders. The same source noted that a significant 80% of those affected resided in low- and middle-income countries. Moreover, individuals with epilepsy tend to have a lower seizure threshold, rendering them more vulnerable to acute repetitive seizures, particularly when triggered by factors like stress or sleep deprivation. Thus, the high burden of acute repetitive seizures is expected to bolster the demand for effective drugs, propelling market growth.
Similarly, a study published in Neurology and Therapy in July 2024 examined the burden of seizures in prehospital settings, focusing on incidence and hospital admission rates. The study found that over the previous two years, Germany had recorded 6,534 suspected seizure-related emergency cases, with a significant proportion resulting in hospital admissions. Consequently, the rising number of individuals experiencing seizures underscores the heightened demand for effective acute treatments, a trend anticipated to propel market growth during the forecast period.
Furthermore, hospital initiatives, such as awareness programs focused on mental health and neurological care, are driving research and development in acute repetitive seizure management, thereby fueling market growth. For instance, in March 2023, Aster Prime Hospitals in Hyderabad, India, partnered with the Walkers Association of Krishna Kant Park to host an awareness program on epilepsy for Purple Day. The program sought to elucidate epilepsy symptoms and their effective treatments. These initiatives are poised to heighten the demand for epilepsy diagnoses, subsequently increasing the need for effective medication, thereby accelerating market growth during the forecast period.
Moreover, increased efforts by companies to develop new drugs for treating seizure clusters are poised to drive market growth in the coming years. For instance, in April 2024, Neurelis Inc. showcased a poster on VALTOCO (a diazepam nasal spray) targeting frequent seizure episodes or seizure clusters in epilepsy patients aged from 6 to 65. The poster highlighted the time to treatment across various subpopulations. Such initiatives underscore the company's dedication to enhancing outcomes for epilepsy patients, suggesting a positive trajectory for market growth.
Therefore, owing to the rising burden of epilepsy leading to the high risk of experiencing acute repetitive seizures and increasing company activities, the market studied is expected to grow over the forecast period. However, the high cost of treatment and side effects associated with the drugs are likely to impede market growth over the forecast period.
Acute Repetitive Seizures Market Trends
Benzodiazepines Segment Expected to Witness Significant Growth Over the Forecast Period
Benzodiazepines, often referred to as rescue medications, are a class of drugs predominantly utilized for managing acute repetitive seizures, owing to their rapid action and proven effectiveness. These medications amplify the effects of gamma-aminobutyric acid (GABA), a key inhibitory neurotransmitter. They bolster neuronal inhibition, effectively soothing the overactive brain activity that precipitates seizures. Commonly used benzodiazepines include diazepam, lorazepam, midazolam, and clonazepam.
The benzodiazepine segment of the acute repetitive seizures market is expected to witness significant growth over the forecast period. Factors such as the high number of benzodiazepine drugs available in the market, new product launches, and the rapid efficacy of benzodiazepines in providing quick seizure control make them a preferred choice in emergencies.
Numerous studies have assessed the efficacy of diazepam nasal spray in halting seizure clusters in epilepsy. For instance, a February 2024 article published in Neurology and Therapy highlighted that researchers found earlier administration of the diazepam nasal spray resulted in quicker resolution of seizures within a cluster. These findings underscore diazepam's potency in curbing acute repetitive seizures, likely leading to heightened adoption by healthcare professionals and caregivers, thereby propelling segment growth.
Similarly, multiple studies have scrutinized rescue therapies, particularly benzodiazepines, for managing seizure clusters or acute repetitive seizures in epilepsy. For instance, an article published in Neurology and Therapy in October 2023 noted that community-administered rescue medications could effectively halt a seizure cluster, with benzodiazepines being the primary choice. Intranasal benzodiazepines are favored for their user-friendliness, ensuring satisfaction for both patients and caregivers, whether pediatric or adult. Furthermore, medications like diazepam rectal gel, midazolam nasal spray, and diazepam nasal spray have received specific approvals as rescue treatments for seizure clusters. Such studies are likely to fuel the demand for benzodiazepine drugs in the market, bolstering segment growth.
Moreover, as regulatory bodies continue to approve new products and grant drug designations, the demand for benzodiazepines is poised to rise. This surge in demand is expected to fuel segment growth during the forecast period. For instance, in November 2023, Aculys Pharma Inc. secured an orphan drug designation from Japan's Ministry of Health, Labour and Welfare for its diazepam nasal spray (NRL-1). This antiepileptic drug, currently in development, targets the treatment of epileptic seizures, specifically status epilepticus. Such advancements are likely to motivate companies to invest in treatments for conditions linked to acute repetitive seizures, further propelling segment growth.
Therefore, owing to the rising number of research studies related to benzodiazepines and new product approvals and drug designations, the segment studied is anticipated to grow over the forecast period.
North America Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to witness significant growth in the acute repetitive seizures market over the forecast period. The rising burden of neurological disorders leads to substantial demand for acute repetitive seizure treatment, investments in research and development activities, and growing awareness initiatives and campaigns in the region, which are expected to drive market growth over the forecast period.
Researchers have conducted various studies to assess the effectiveness of midazolam nasal spray in managing seizure clusters. For instance, a March 2023 article published in the American Journal of Managed Care highlighted the efficacy and safety of midazolam nasal spray (MDZ-NS) in managing seizure clusters in epilepsy patients. The study found that patients administered a 5-mg dose of MDZ-NS either remained seizure-free for over six hours or had their seizures terminated within 10 minutes, with no recurrences in the 10-minute to six-hour window. These findings position MDZ-NS as a promising alternative to established rescue medications for seizure clusters, suggesting a potential uptick in its adoption and, consequently, market growth.
Furthermore, the increasing focus of researchers on developing new drugs for the treatment of acute repetitive seizures is anticipated to fuel the availability of novel drugs in the region and is expected to augment market growth over the forecast period. For instance, in October 2023, NYU Grossman School of Medicine’s researchers conducted a Phase 2b clinical trial. Their findings indicated that patients incorporating XEN1101 into their existing antiseizure regimen experienced a 33% to 53% reduction in monthly seizures, contingent on the dosage. This underscores XEN1101's potential as a rapid, safe, and effective treatment for focal epilepsy. As a potassium-channel opener, XEN1101 works by enhancing potassium flow out of nerves, thereby preventing seizures. Such developments are expected to fuel the availability of novel drugs in the market and spur market growth over the forecast period.
Moreover, regulatory bodies' recent drug approvals are equipping healthcare professionals with a wider array of effective treatments, leading to enhanced patient outcomes and satisfaction. This trend is anticipated to drive market growth during the forecast period. For instance, in April 2024, Aquestive Therapeutics secured approval from the United States Food and Drug Administration for its Libervant (diazepam) Buccal Film, aimed at treating seizure clusters in children between two and five years of age. The introduction of libervant marks a novel approach to administering diazepam, specifically for managing acute repetitive seizure emergencies in the targeted age group. Thus, such approvals are expected to fuel the availability of novel drugs for treating acute repetitive seizures, bolstering market growth.
Therefore, with the growing number of drug approvals, increasing research and development activities by researchers, and the rising number of research studies evaluating the safety and effectiveness of seizure cluster drugs in patients across North America, the market studied is expected to grow over the forecast period.
Acute Repetitive Seizures Industry Overview
The acute repetitive seizures market is semi-consolidated in nature. Key players in the market focus on developing and marketing rescue medications, including benzodiazepines and new anticonvulsants. Some of the key players in the market are Neurelis Inc., UCB SA Belgium, Aquestive Therapeutics, Eisai Co. Ltd, and H. Lundbeck AS.
Acute Repetitive Seizures Market Leaders
-
UCB S.A., Belgium
-
Aquestive Therapeutics
-
Eisai Co., Ltd
-
H. Lundbeck A/S
-
Neurelis, Inc.
*Disclaimer: Major Players sorted in no particular order
Acute Repetitive Seizures Market News
- September 2024: Aculys Pharma Inc. submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for diazepam nasal spray, an antiepileptic drug being developed for the treatment of status epilepticus or epileptic seizures that may lead to status epilepticus.
- March 2024: The Epilepsy Foundation partnered with Iaso Venture to establish the Iaso NeuroImpact Fund. This innovative fund serves as a cornerstone for advancing the development of pioneering therapeutics aimed at revolutionizing the landscape of care for epilepsy and seizure disorders.
Acute Repetitive Seizures Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Seizures Coupled with Growing Aging Population
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 High Cost of Treatment and Various Side Effects Associated with Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Drug Type
5.1.1 Benzodiazepines
5.1.2 Antiepileptic Drugs
5.1.3 Barbiturates
5.1.4 Other Drug Types (Anticonvulsants, Anesthetic Drugs)
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Injectables
5.2.3 Other Routes of Administration (Nasal, Rectal, Buccal, and Parenteral)
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 UCB SA Belgium
6.1.2 Aculys Pharma Inc.
6.1.3 Aquestive Therapeutics
6.1.4 Neurelis
6.1.5 Eisai Co. Ltd
6.1.6 Pfizer Inc.
6.1.7 H. Lundbeck AS
6.1.8 Teva Pharmaceutical Industries Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Acute Repetitive Seizures Industry Segmentation
As per the scope of the report, acute repetitive seizures are characterized by multiple seizures happening within a brief timeframe, usually within 24 hours. This condition can be triggered by several factors, such as acute brain injuries, infections, metabolic imbalances, or withdrawal from specific substances. In contrast to epilepsy, where seizures are recurrent, acute repetitive seizures are often instigated by immediate medical concerns.
The acute repetitive seizures market is segmented by drug type, routes of administration, distribution channel, and geography. By drug type, the market is segmented into benzodiazepines, antiepileptic drugs, barbiturates, and other drug types. The other drug types segment includes anticonvulsants and general anesthesia drugs. By route of administration, the market is segmented into oral, injectable, and other routes of administration. The other routes of administration segment includes nasal, rectal, buccal, and parenteral. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market sizing and forecasts have been done based on value (USD).
By Drug Type | |
Benzodiazepines | |
Antiepileptic Drugs | |
Barbiturates | |
Other Drug Types (Anticonvulsants, Anesthetic Drugs) |
By Route of Administration | |
Oral | |
Injectables | |
Other Routes of Administration (Nasal, Rectal, Buccal, and Parenteral) |
By Distribution Channel | |
Hospital Pharmacies | |
Retail Pharmacies | |
Online Pharmacies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Acute Repetitive Seizures Market Research FAQs
How big is the Acute Repetitive Seizures Market?
The Acute Repetitive Seizures Market size is expected to reach USD 2.62 billion in 2024 and grow at a CAGR of 13.05% to reach USD 4.84 billion by 2029.
What is the current Acute Repetitive Seizures Market size?
In 2024, the Acute Repetitive Seizures Market size is expected to reach USD 2.62 billion.
Who are the key players in Acute Repetitive Seizures Market?
UCB S.A., Belgium, Aquestive Therapeutics, Eisai Co., Ltd, H. Lundbeck A/S and Neurelis, Inc. are the major companies operating in the Acute Repetitive Seizures Market.
Which is the fastest growing region in Acute Repetitive Seizures Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Acute Repetitive Seizures Market?
In 2024, the North America accounts for the largest market share in Acute Repetitive Seizures Market.
What years does this Acute Repetitive Seizures Market cover, and what was the market size in 2023?
In 2023, the Acute Repetitive Seizures Market size was estimated at USD 2.28 billion. The report covers the Acute Repetitive Seizures Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Acute Repetitive Seizures Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Acute Repetitive Seizures Industry Report
Statistics for the 2024 Acute Repetitive Seizures market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Acute Repetitive Seizures analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.